Table 1 Summary of characteristics, study outcomes and details of addressing and reporting adherence in the randomized controlled trials included in the study
Reference | Year of publication | Population | Total N (Intervention/Control) | Therapy (Intervention/Control) | Trial outcome | Reported Adherence | Addressing Adherence | Drug discontinuation: Intervention/Control arms |
|---|---|---|---|---|---|---|---|---|
Baigent et al. [9] | 2011 | HD & PDa | 3023 (1533/1490)b | Simvastain + Ezetimibe/Placebo | Negativeb,c | 65%b in the Inter-vention group | Run-in phase to identify non-compliers | 33%/36%e,f |
Block et al. [26] | 2007 | HD | 127 (60/67) | Sevalamer/Ca based binders | Positive | Not reported | Specified as not checked | Not reported |
Chertow et al. [17] | 2012 | HD | 3883 (1948/1935) | Cinacalcet/Placebo | Negative | Not reported | TNA reported as cause of therapy discontinuation. Reports lag censored analysis after therapy cessation | 67%/71%f,g,h |
Cice et al. [24] | 2010 | HD | 332 (165/167) | Add-on Telmisartan (to ACEI)/Placebo | Positive | Not reported | Not addressed | 16/11%f,i |
Di Iorio et al. [27] | 2013 | HD | 466 (232/234) | Sevalamer/Ca based binders | Positive | Not reported | Not addressed | 14%/15%i |
Dixon et al. [28] | 2009 | HD | 649 (321/328) | Dipyridamole + Aspirin/Placebo | Negatived | 83%/83% | Assessed by pill count & reported | 30%/26%f,i |
Fellstrom et al. [10] | 2009 | HD | 2773 (1389/1384) | Rosuvastatin/Placebo | Negative | 92%/86% | Assessed by pill count & reported | 73%/74%f,g,h,i,j |
Iseki et al. [25] | 2013 | HD | 469 (235/234) | Olmesartan/Usual care but No ARB or ACEI | Negative | Not reported | Not addressed | 49% in interventionf,h |
Jamison et al. [19] | 2007 | HD & PDa | 751 (372/379)b | Folic acid + B6 + B12/Placebo | Negative | 85%/87% | Assessed by pill count & reported | 27%/26%i |
Lok et al. [32] | 2012 | HD | 196 (99/97) | Fish oil/Placebo | Positived | Not reported | Blood tests supporting drug effect reported, but not at patient level | 16%/16%i,j |
Matsumoto et al. [30] | 2014 | HD | 309 (157/152) | Spironolactone/Usual care | Positive | Not reported | Non-adherent patients excluded from participation | 29%/16%f |
Nishimura et al. [29] | 2009 | HD | 129 (64 + 65) | Nicorandil/Usual care but no Nicorandil | Positive | Not reported | Not addressed | 0%/0% |
Righetti et al. [31] | 2006 | HD | 88 (37/51) | Folic acid/Usual care | Positive | Not reported | Reported as measured, but not reported | 72% e,f,h,I,j |
Stegmayr et al. [11] | 2005 | HD & PDa | 110 (53/57)b | Atorvastatin/Placebo | Negative | Not reported | Non-adherent patients excluded from participation | 33%/6%f |
Suki et al. [15] | 2007 | HD | 2103 (1053/1050) | Sevalamer/Ca based binders | Negative | Not reported | TNA reported as cause of therapy discontinuation | 48%/51%f,g,h |
Suzuki et al. [22] | 2008 | HD | 366 (183/183) | Any ARB/Usual care but no ARB | Positive | Not reported | Not addressed | 2%/2%f |
Svensson et al. [14] | 2006 | HD | 206 (103/103) | Omacor (3-PUFA)/Placebo | Negative | Not reported | Non-adherent patients excluded, Blood tests supporting drug effect reported, but patient level adherence not reported | 27%/22%f,g |
Takahashi et al. [21] | 2006 | HD | 80 (43/37) | Candesartan/Usual care | Positive | Not reported | Non-adherent patients excluded from participation | 0%/0% |
Tepel et al. [23] | 2008 | HD | 251 (123/128) | Amlodipine/Placebo | Negative | Not reported | TNA reported as cause of therapy discontinuation | 63%/65%f,g,h,i,j |
Wanner et al. [8] | 2005 | HD | 1255 (619/636) | Atorvastatin/Placebo | Negative | 80%/82% | Assessed by pill count & reported | 23%/24%f |
Wilson et al. [16] | 2009 | HD | 1354 (680/674) | Lanthanum/Usual care | Negative | Not reported | Not addressed | 72%/53%f,g,h,i,j |
Zannad et al. [20] | 2006 | HD | 397 (196/201) | Fosinopril/Placebo | Negative | Not reported | Not addressed | 4%/5%h |